Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Bioorganic & Medicinal Chemistry Letters|September 5, 2006
N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists IIJason M Elliott, Robert W Carling, Gary G Chicchi, et al.European Journal of Cancer (Oxford, England : 1990)|March 14, 2025
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusionsAmi V Desai, Aditi Bagchi, Amy E Armstrong, et al.Journal for Immunotherapy of Cancer|October 24, 2020
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patientsJean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2017
89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid TumorsFrederike Bensch, Laetitia E Lamberts, Michaël M Smeenk, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid TumorsDidier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, et al.Investigational New Drugs|January 20, 2018
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancerAndreas Schneeweiss, Tjoung-Won Park-Simon, Joan Albanell, et al.The Lancet. Oncology|July 17, 2015
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 studyPhilippe A Cassier, Antoine Italiano, Carlos A Gomez-Roca, et al.Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.Neuro-Oncology|April 8, 2022
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)Ami V Desai, Giles W Robinson, Karen Gauvain, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2017
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical ActivityDidier Meulendijks, Wolfgang Jacob, Emile E Voest, et al.Pageof 4